SCHEMBL30830848

SCHEMBL30830848

CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccc(C(=O)N3CCN(c4cc5c(cc4F)C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)cc2)C1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 10/20 0.50
▸ KAT2B Q92831 7/20 0.49
▸ BRD9 Q9H8M2 3/20 0.49
▸ BRD1 O95696 1/20 0.49
▸ ACHE P22303 1/20 0.49
▸ BRPF1 P55201 1/20 0.49
▸ BPTF Q12830 1/20 0.49
▸ KAT2A Q92830 1/20 0.49
▸ BRD7 Q9NPI1 1/20 0.49
▸ BAZ2B Q9UIF8 1/20 0.49
▸ BRPF3 Q9ULD4 1/20 0.49
▸ PLK4 O00444 1/20 0.39
▸ IKZF3 Q9UKT9 1/20 0.38
▸ HPGDS O60760 2/20 0.36
▸ AR P10275 1/20 0.36
▸ DDB1 Q16531 3/20 0.34
▸ MAP1LC3B Q9GZQ8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830849 0.90 KAT2B (0.51) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830616 0.89 KAT2B (0.51) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830919 0.89 CRBN (0.50) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830694 0.87 KAT2B (0.53) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830584 0.86 KAT2B (0.47) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830651 0.86 KAT2B (0.48) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830904 0.86 KAT2B (0.49) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830793 0.86 CRBN (0.50) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830618 0.86 KAT2B (0.47) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830659 0.85 KAT2B (0.50) CRBNKAT2BBRD9BRD1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback